Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.

Mol Cancer Ther 2018 06 27;17(6):1324-1331. Epub 2018 Mar 27.

Yale School of Medicine, Medical Oncology, New Haven, Connecticut.

Our aim was to examine the association of pretreatment tumor-infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical trial, which randomized patients to bevacizumab + nab-paclitaxel, followed by doxorubicin/cyclophosphamide (AC) versus two control arms without bevacizumab (varying sequence of AC and nab-paclitaxel). TILs were assessed in 124 pre- and 62 posttreatment tissues (including 59 pairs). PD-L1 was assessed in 120 pre- and 43 posttreatment tissues (including 39 pairs) using the 22C3 antibody. Baseline and treatment-induced immune changes were correlated with pCR and survival using estrogen receptor (ER) and treatment-adjusted logistic and Cox regressions, respectively. At baseline, the mean TIL count was 17.4% (17% had zero TILs, 9% had ≥50% TILs). Posttreatment, mean TIL count decreased to 11% (5% had no TILs, 2% had >50% TILs). In paired samples, the mean TIL change was 15% decrease. Baseline PD-L1 was detected in 43% of cases ( = 5 in tumor cells, = 29 stroma, = 18 tumor + stroma). Posttreatment, PD-L1 expression was not significantly lower (33%). Higher baseline TIL count and PD-L1 positivity rate were associated with higher pCR rate even after adjustment for treatment and ER status ( = 0.018). There was no association between TIL counts, PD-L1 expression, and survival due to few events. In conclusion, TIL counts, but not PD-L1 expression, decreased significantly after treatment. Continued PD-L1 expression in some residual cancers raises the possibility that adjuvant immune checkpoint inhibitor therapy could improve survival in this patient population. .

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548451PMC
June 2018
48 Reads
5.680 Impact Factor

Publication Analysis

Top Keywords

pd-l1 expression
20
pre- posttreatment
12
pd-l1
9
including pairs
8
counts pd-l1
8
baseline count
8
tissues including
8
posttreatment tissues
8
count pd-l1
8
expression
5
posttreatment
5
tils
5
stroma tumor
4
pairs pd-l1
4
tumor stroma
4
120 pre-
4
pairs 22c3
4
cases tumor
4
22c3 antibody
4
tumor cells
4

Similar Publications